427 related articles for article (PubMed ID: 17680350)
1. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Manzano A; Pérez-Segura P
ScientificWorldJournal; 2012; 2012():327341. PubMed ID: 22649288
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of familial adenomatous polyposis.
Lynch PM
Fam Cancer; 2016 Jul; 15(3):467-75. PubMed ID: 27083160
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
8. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase as a target for colorectal cancer chemoprevention.
Moreira L; Castells A
Curr Drug Targets; 2011 Dec; 12(13):1888-94. PubMed ID: 21158711
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention in familial adenomatous polyposis.
Kim B; Giardiello FM
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):607-22. PubMed ID: 22122775
[TBL] [Abstract][Full Text] [Related]
11. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib as adjunctive therapy for treatment of colorectal cancer.
North GL
Ann Pharmacother; 2001 Dec; 35(12):1638-43. PubMed ID: 11793634
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of colorectal cancer: slow, steady progress.
Burke CA; Bauer WM; Lashner B
Cleve Clin J Med; 2003 Apr; 70(4):346-50. PubMed ID: 12701989
[TBL] [Abstract][Full Text] [Related]
14. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of colorectal cancer: two steps forward, one step back?
Half EE; Arber N
Future Oncol; 2006 Dec; 2(6):697-704. PubMed ID: 17155896
[TBL] [Abstract][Full Text] [Related]
17. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
Thun MJ; Henley SJ; Patrono C
J Natl Cancer Inst; 2002 Feb; 94(4):252-66. PubMed ID: 11854387
[TBL] [Abstract][Full Text] [Related]
19. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis.
Yang VW; Geiman DE; Hubbard WC; Spannhake EW; Hylind LM; Hamilton SR; Giardiello FM
Prostaglandins Other Lipid Mediat; 2000 Jan; 60(1-3):83-96. PubMed ID: 10680778
[TBL] [Abstract][Full Text] [Related]
20. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.
Boon EM; Keller JJ; Wormhoudt TA; Giardiello FM; Offerhaus GJ; van der Neut R; Pals ST
Br J Cancer; 2004 Jan; 90(1):224-9. PubMed ID: 14710233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
